Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.

Virus research - 2 Dec 2015

Tai S-H Sheldon, Agafitei Olga, Gao Zhizeng, Liggins Richard, Petric Martin, Withers Stephen G, Niikura Masahiro

Abstract excerpt

Neuraminidase inhibitors (NAIs), including the most frequently prescribed oral therapeutic oseltamivir, play a critical role in the control of severe influenza virus (IFV) infections. However, recent reports of spread of an oseltamivir-resistant H1N1 pandemic strain in individuals who have never been exposed to oseltamivir highlight an urgent need for new antivirals against NAI-resistant IFVs. Difluorosialic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Influenza A Virus, H1N1 Subtype
Share to Influenza A Virus, H3N2 Subtype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Madin Darby Canine Kidney Cells

Share to Neuraminidase

Share to Oseltamivir

Share to Serial Passage

Share to Sialic Acids

Share to Virus Cultivation

Source

Identifiers

PMID: 26247418
DOI: 10.1016/j.virusres.2015.07.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.PMID 26247418Read ↗

Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.Semantic proximity Read ↗

Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.Semantic proximity Read ↗

Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitnessSemantic proximity Read ↗

Structural basis for oseltamivir resistance of influenza viruses.Semantic proximity Read ↗

Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors.Semantic proximity Read ↗

Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.Semantic proximity Read ↗

Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.Semantic proximity Read ↗

An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality.Semantic proximity Read ↗

In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivirSemantic proximity Read ↗

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.Semantic proximity Read ↗

Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.Semantic proximity Read ↗

Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.